Skip to main content

 Related scientific articles (all)

Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02.

Authors : Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T
Year : 2013
Journal : Blood
Volume : 121(11)
Pages : 1968-75

Is it possible to improve the breaking bad news skills of residents when a relative is present? A randomised study.

Authors : Merckaert I, Liénard A, Libert Y, Bragard I, Delvaux N, Etienne AM, Marchal S, Meunier J, Reynaert C, Slachmuylder JL, Razavi D
Year : 2013
Journal : Br J Cancer
Volume : 109(10)
Pages : 2507-14

Change in the microenvironment of breast cancer studied by FTIR imaging.

Authors : Kumar S, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Year : 2013
Journal : Analyst
Volume : 138(14)
Pages : 4058-65

Personalized therapy for breast cancer: a dream or a reality?

Authors : Zardavas D, Pugliano L, Piccart-Gebhart M
Year : 2013
Journal : Future Oncol
Volume : 9(8)
Pages : 1105-19

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.

Authors : Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart-Gebhart M, Joensuu H, Sotiriou C
Year : 2013
Journal : J. Natl. Cancer Inst.
Volume : 105(13)
Pages : 960-967

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.

Authors : Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(1)
Pages : e53292

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Authors : Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Müller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Year : 2013
Journal : Breast Cancer Res
Volume : 15(5)
Pages : R86

Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding.

Authors : Verdonck M, Wald N, Janssis J, Yan P, Meyer C, Legat A, Speiser DE, Desmedt C, Larsimont D, Sotiriou C, Goormaghtigh E
Year : 2013
Journal : Analyst
Volume : 138(14)
Pages : 4083-91

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Authors : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pages : 2621-32

Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors : Metzger-Filho O, Catteau A, Michiels S, Buyse M, Ignatiadis M, Saini KS, de Azambuja E, Fasolo V, Naji S, Canon JL, Delrée P, Coibion M, Cusumano P, Jossa V, Kains JP, Larsimont D, Richard V, Faverly D, Cornez N, Vuylsteke P, Vanderschueren B, Peyro-Saint-Paul H, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : PLoS One
Volume : 8(8)
Pages : e66848

Luminal breast cancer: from biology to treatment.

Authors : Ignatiadis M, Sotiriou C
Year : 2013
Journal : Nat Rev Clin Oncol
Volume : 10(9)
Pages : 494-506

Evaluation of the effect of computer-aided classification of benign and malignant lesions on reader performance in automated three-dimensional breast ultrasound.

Authors : Tan T, Platel B, Twellmann T, van Schie G, Mus R, Grivegnée A, Mann RM, Karssemeijer N
Year : 2013
Journal : Acad Radiol
Volume : 20(11)
Pages : 1381-8

Planning cancer control in Latin America and the Caribbean.

Authors : Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis JS, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G
Year : 2013
Journal : Lancet Oncol
Volume : 14(5)
Pages : 391-436

Personalised cancer management: closer, but not here yet.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial.

Authors : Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, Casasnovas RO, Van Den Neste E, Dechene J, De Maertelaer V, Bron D, Englert Y
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(7)
Pages : 903-9

How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer.

Authors : Pinto AC, de Azambuja E, Piccart-Gebhart M
Year : 2013
Journal : Breast Care (Basel)
Volume : 8(4)
Pages : 264-269

Asthma control measurement using five different questionnaires: A prospective study.

Authors : Vermeulen F, de Meulder I, Paesmans M, Muylle I, Bruyneel M, Ninane V
Year : 2013
Journal : Respir Med
Volume : 107(9)
Pages : 1314-21

Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.

Authors : Saghatchian M, Mook S, Pruneri G, Viale G, Glas AM, Guerin S, Cardoso F, Piccart-Gebhart M, Tursz T, Delaloge S, van t Veer L
Year : 2013
Journal : Breast
Volume : 22(5)
Pages : 682-90

Distinct tumor protein p53 mutants in breast cancer subgroups.

Authors : Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H
Year : 2013
Journal : Int. J. Cancer
Volume : 132(5)
Pages : 1227-31

TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.

Authors : Moretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A
Year : 2013
Journal : Future Oncol
Volume : 9(10)
Pages : 1477-87